The Fanconi road to cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

36 citing papers in PubMed.

1. Fanconi anemia caused by biallelic inactivation of BRCA2 can present with an atypical cancer phenotype in adulthood.Clinical genetics · 2023
   Article
2. Epigenetic Regulation of Fanconi Anemia Genes Implicates PRMT5 Blockage as a Strategy for Tumor Chemosensitization.Molecular cancer research : MCR · 2021
   Article
3. An update on Fanconi anemia: Clinical, cytogenetic and molecular approaches (Review).Biomedical reports · 2021
   Review
4. Differentiation of MISSLA and Fanconi anaemia by computer-aided image analysis and presentation of two novel MISSLA siblings.European journal of human genetics : EJHG · 2019
   Article
5. A new look at molecular biology of breast cancer.Cancer biology & therapy · 2019
   Review
6. Lymphopenia With Clinical and Laboratory Features of Combined Immune Deficiency in an 11-Year-Old Female WithFrontiers in pediatrics · 2018
   Article
7. FANCD2 and DNA Damage.International journal of molecular sciences · 2017
   Review
8. Involvement of FANCD2 in Energy Metabolism via ATP5α.Scientific reports · 2017
   Article
9. Overlooked FANCD2 variant encodes a promising, portent tumor suppressor, and alternative polyadenylation contributes to its expression.Oncotarget · 2017
   Article
10. TNF-α signaling in Fanconi anemia.Blood cells, molecules & diseases · 2014
    Review
11. Advances in the understanding of the Fanconi anemia tumor suppressor pathway.Cancer biology & therapy · 2013
    Review
12. Fanconi anemia signaling network regulates the spindle assembly checkpoint.The Journal of clinical investigation · 2013
    Article
13. The WD40-repeat protein-containing deubiquitinase complex: catalysis, regulation, and potential for therapeutic intervention.Cell biochemistry and biophysics · 2013
    Review
14. 5-Aza-2'-deoxycytidine causes replication lesions that require Fanconi anemia-dependent homologous recombination for repair.Nucleic acids research · 2013
    Article
15. FAVL impairment of the Fanconi anemia pathway promotes the development of human bladder cancer.Cell cycle (Georgetown, Tex.) · 2012
    Article
16. RAD51C: a novel cancer susceptibility gene is linked to Fanconi anemia and breast cancer.Carcinogenesis · 2010
    Review
17. FAVL elevation in human tumors disrupts Fanconi anemia pathway signaling and promotes genomic instability and tumor growth.The Journal of clinical investigation · 2010
    Article
18. Inactivation of the tumor suppressor genes causing the hereditary syndromes predisposing to head and neck cancer via promoter hypermethylation in sporadic head and neck cancers.ORL; journal for oto-rhino-laryngology and its related specialties · 2010
    Article
19. The Fanconi anemia/BRCA gene network in zebrafish: embryonic expression and comparative genomics.Mutation research · 2009
    Review
20. DNA damage response pathways in tumor suppression and cancer treatment.World journal of surgery · 2009
    Review

Corrections and comments

• Comment on
  Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice.2003

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as